Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the Bio-IT World Conference and Expo occurring May 3-5, 2022 in Boston, MA.
Kas Subramanian, PhD, Executive Director of Modeling at Applied BioMath will present “Applications of Machine Learning in Preclinical Drug Discovery” within the conference track, AI for Drug Discovery and Development on Thursday, May 5, 2022 at 1:05 p.m. E.T. In this presentation, Dr. Subramanian will discuss how machine learning methods can improve efficiency in therapeutic R&D decision making. He will review case studies that demonstrate machine learning applications to target validation and lead optimization.
“Traditionally, therapeutic R&D requires experiments on many different targets, hits, leads, and candidates that are based on best guesses,” said John Burke, PhD, Co-founder, President and CEO of Applied BioMath. “By utilizing artificial intelligence and machine learning, project teams can computationally work with more data to better inform experiments and develop better therapeutics.”
To learn more about Applied BioMath’s presence at the Bio-IT World Conference and Expo, please visit www.appliedbiomath.com/BioIT22.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.
